dc.contributor.author | Mpoza, Edward | |
dc.contributor.author | Mukaremera, Liliane | |
dc.contributor.author | Kundura, Didas Atwebembere | |
dc.contributor.author | Akampurira, Andrew | |
dc.contributor.author | Luggya, Tonny | |
dc.contributor.author | Tadeo, Kiiza Kandole | |
dc.contributor.author | Pastick, Katelyn A. | |
dc.contributor.author | Bridge, Sarah C. | |
dc.contributor.author | Tugume, Lillian | |
dc.contributor.author | Kiggundu, Reuben | |
dc.contributor.author | Musubire, Abdu K. | |
dc.contributor.author | Williams, Darlisha A. | |
dc.contributor.author | Muzoora, Conrad | |
dc.contributor.author | Nalintya, Elizabeth | |
dc.contributor.author | Rajasingham, Radha | |
dc.contributor.author | Rhein, Joshua | |
dc.contributor.author | Boulware, David R. | |
dc.contributor.author | Meya, David B. | |
dc.contributor.author | Abassi, Mahsa | |
dc.date.accessioned | 2022-06-13T12:48:54Z | |
dc.date.available | 2022-06-13T12:48:54Z | |
dc.date.issued | 2018 | |
dc.identifier.citation | Mpoza, E., Mukaremera, L., Kundura, D. A., Akampurira, A., Luggya, T., Tadeo, K. K., ... & Abassi, M. (2018). Evaluation of a point-of-care immunoassay test kit ‘StrongStep’for cryptococcal antigen detection. PLoS One, 13(1), e0190652. | en_US |
dc.identifier.uri | http://ir.must.ac.ug/xmlui/handle/123456789/2105 | |
dc.description.abstract | Background: HIV-associated cryptococcal meningitis is the leading cause of adult meningitis in Sub- Saharan Africa, accounting for 15%±20% of AIDS-attributable mortality. The development of point-of-care assays has greatly improved the screening and diagnosis of cryptococcal disease. We evaluated a point-of-care immunoassay, StrongStep (Liming Bio, Nanjing, Jiangsu, China) lateral flow assay (LFA), for cryptococcal antigen (CrAg) detection in cerebrospinal fluid (CSF) and plasma.
Methods: We retrospectively tested 143 CSF and 77 plasma samples collected from HIV-seropositive individuals with suspected meningitis from 2012±2016 in Uganda. We prospectively tested 90 plasma samples collected from HIV-seropositive individuals with CD4 cell count <100
cells/μL from 2016±2017 as part of a cryptococcal antigenemia screening program. The StrongStep CrAg was tested against a composite reference standard of positive Immy CrAg LFA (Immy, Norman, OK, USA) or CSF culture with statistical comparison by McNemar's test.
Results: StrongStep CrAg had a 98% (54/55) sensitivity and 90% (101/112) specificity in plasma (P = 0.009, versus reference standard). In CSF, the StrongStep CrAg had 100% (101/101) sensitivity and 98% (41/42) specificity (P = 0.99). Adjusting for the cryptococcal antigenemia prevalence of 9% in Uganda and average cryptococcal meningitis prevalence of 37% in Sub-Saharan Africa, the positive predictive value of the StrongStep CrAg was 50% in plasma and 96% in CSF
Conclusions: We found the StrongStep CrAg LFA to be a sensitive assay, which unfortunately lacked specificity in plasma. In lower prevalence settings, a majority of positive results from blood
would be expected to be false positives. | en_US |
dc.description.sponsorship | National Institutes of Neurologic Diseases and Stroke and Fogarty International Center, R01NS086312, | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | PLoS One | en_US |
dc.subject | Test kit | en_US |
dc.subject | Cryptococcal antigen detection | en_US |
dc.subject | HIV-associated | en_US |
dc.subject | A point-of-care immunoassay | en_US |
dc.subject | StrongStep (Liming Bio | en_US |
dc.subject | Plasma | en_US |
dc.title | Evaluation of a point-of-care immunoassay test kit `StrongStep' for cryptococcal antigen detection | en_US |
dc.type | Article | en_US |